文献速递临床免疫

基于Fcγ受体的ELISA法灵敏、特异且持久地检测人血清中抗SARS-CoV-2核衣壳蛋白IgG抗体

Fcγ-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera.
PubMed 文献 · J Clin Microbiol · 2022-05-16

该研究开发了两种基于Fcγ受体捕获抗原-抗体复合物、以截短核衣壳蛋白为抗原的SARS-CoV-2 IgG ELISA,并用35例COVID-19患者的213份纵向血清样本和790份COVID-19前阴性样本进行验证。两种 assay 在早期恢复期敏感性相似,但ELISA 2(更高血清浓度)可在感染后显著更长时间(≥15个月)检测到IgG,且对IIFT滴度≤1:640样本的分析敏感性显著更高,高滴度样本出现前带效应。两种ELISA特异性优异,适用于血清阳性率研究。

要点

  • ELISA 2采用更高血清浓度,可在感染后≥15个月检测抗SARS-CoV-2核衣壳IgG。
  • 对IIFT滴度≤1:640样本,ELISA 2的分析敏感性显著高于ELISA 1;高滴度样本出现前带效应。
  • 两种ELISA对欧洲、亚洲、南美洲及非洲挑战性样本 panel 均显示优异特异性。

核心结论

  • 基于FcγR的SARS-CoV-2核衣壳IgG ELISA组合了溶液中抗原-抗体结合与免疫复合物的同种型特异检测,是血清阳性率研究的有价值工具。
  • ELISA 2可在感染后≥15个月检测IgG,适用于需长期检测抗体且免疫背景复杂或已开展spike蛋白疫苗计划的人群。

研究设计与样本

  • 开发两种SARS-CoV-2 IgG ELISA,采用专利平台技术以固相结合FcγR捕获抗原-抗体复合物、截短核衣壳蛋白为抗原,两种 assay 血清和抗原稀释度不同。
  • 验证使用35例COVID-19患者的213份纵向血清样本和790份来自全球不同地区的COVID-19前阴性对照样本。

主要发现

  • 两种 assay 在早期恢复期诊断敏感性相似,但ELISA 2(更高血清浓度)可在感染后显著更长时间(≥15个月)检测SARS-CoV-2 IgG抗体。
  • 参照间接免疫荧光试验(IIFT),ELISA 2在滴度≤1:640样本中分析敏感性显著更高;高滴度样本中ELISA 2出现前带效应。
  • 两种ELISA对欧洲、亚洲和南美洲的COVID-19前血清样本以及多个挑战性非洲样本 panel 均显示优异特异性。

关键数值与推荐

  • ELISA 2可在感染后≥15个月检测SARS-CoV-2 IgG抗体。
  • ELISA 2对IIFT滴度≤1:640样本的分析敏感性显著高于ELISA 1;高滴度样本出现前带效应。
  • 两种ELISA对欧洲、亚洲、南美洲COVID-19前样本及多个挑战性非洲样本 panel 特异性优异。

临床怎么用

  • 在需长期检测抗SARS-CoV-2 IgG的血清阳性率研究中,可优先选用ELISA 2以延长检测窗口。
  • 对高滴度样本需注意ELISA 2的前带效应,必要时稀释复核。
  • 在免疫背景复杂或已开展spike蛋白疫苗计划的人群中,基于核衣壳蛋白的FcγR ELISA可减少spike疫苗诱导抗体的干扰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sensitive and specific serological tests are mandatory for epidemiological studies evaluating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence as well as coronavirus disease 2019 (COVID-19) morbidity and mortality rates. The accuracy of results is challenged by antibody waning after convalescence and by cross-reactivity induced by previous infections with other pathogens. By employing a patented platform technology based on capturing antigen-antibody complexes with a solid-phase-bound Fcγ receptor (FcγR) and truncated nucleocapsid protein as the antigen, two SARS-CoV-2 IgG enzyme-linked immunosorbent assays (ELISAs), featuring different serum and antigen dilutions, were developed. Validation was performed using a serum panel comprising 213 longitudinal samples from 35 COVID-19 patients and a negative-control panel consisting of 790 pre-COVID-19 samples from different regions of the world. While both assays show similar diagnostic sensitivities in the early convalescent phase, ELISA 2 (featuring a higher serum concentration) enables SARS-CoV-2 IgG antibody detection for a significantly longer time postinfection (≥15 months). Correspondingly, analytical sensitivity referenced to indirect immunofluorescence testing (IIFT) is significantly higher for ELISA 2 in samples with a titer of ≤1:640; for high-titer samples, a prozone effect is observed for ELISA 2. The specificities of both ELISAs were excellent not only for pre-COVID-19 serum samples from Europe, Asia, and South America but also for several challenging African sample panels. The SARS-CoV-2 IgG FcγR ELISAs, methodically combining antigen-antibody binding in solution and isotype-specific detection of immune complexes, are valuable tools for seroprevalence studies requiring the (long-term) detection of anti-SARS-CoV-2 IgG antibodies in populations with a challenging immunological background and/or in which spike-protein-based vaccine programs have been rolled out.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Deschermeier C, Ehmen C, von Possel R, et al. Fcγ-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera. J Clin Microbiol. 2022. PMID: 35574677. doi:10.1128/jcm.00075-22

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。